Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Baxter
Moodys
Dow
Merck

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for Forest Laboratories Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2014)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Forest Laboratories Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-05-30
Court District Court, D. Delaware Date Terminated 2016-07-26
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties ADAMAS PHARMACEUTICALS INC.; FOREST LABORATORIES HOLDINGS LTD.; FOREST LABORATORIES INC.; RANBAXY INC.; RANBAXY LABORATORIES LIMITED; TEVA PHARMACEUTICALS USA INC.
Patents 5,061,703; 8,168,209; 8,173,708; 8,283,379; 8,329,752; 8,362,085; 8,598,233
Attorneys Anne E. Li; Anne Li; Ashley Fry; Bindu Ann George Palapura; Chad Michael Shandler; Christopher A. Pinahs; David Ellis Moore; Huiya Wu; Jack B. Blumenfeld; Jeffer Ali; Jennell Bilek; John W. Bateman; Maryellen Noreika; Richard L. Horwitz; Travis Steven Hunter
Firms Morris, Nichols, Arsht & Tunnell; Richards, Layton & Finger, PA
Link to Docket External link to docket
Small Molecule Drugs cited in Forest Laboratories Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Forest Laboratories Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-08-21 27 Patent/Trademark Report to Commissioner Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,039,009; 8,168,209; 8,173,708; 8,283,379…2014 26 July 2016 1:14-cv-00686 830 Patent None District Court, D. Delaware External link to document
2014-05-30 5 Patent/Trademark Report to Commissioner ; 8,173,708 B2; 8,282,379 B2; 8,329,752 B2; 8,362,085 B2; 8,598,233 B2;. (dmp, ) (Entered: 06/02/2014)… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,168,209 B2; …2014 26 July 2016 1:14-cv-00686 830 Patent None District Court, D. Delaware External link to document
2015-03-27 77 Claim Construction Opening Brief the Went patents”); U.S. Patent No. 8,039,009 (“the ‘009 patent”); and U.S. Patent No. 5,061,703 (“the …Defendants’ infringement of eight United States patents: U.S. Patent Nos. 8,168,209, 8,173,708, 8,283,379, 8,…the ‘703 patent”). The claims of the ‘703 patent are not at issue with respect to claim construction. 1… The six Went patents are related. The ‘209, ‘708, ‘752, ‘085, and ‘233 patents share the same specification… disclosures to the other Went patents. (Ex. A-4). The Went patents are assigned to Plaintiff Adamas External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Johnson and Johnson
Medtronic
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.